JANX241220C40000
- 10.90
- 0.000.00%
Janux Therapeutics Newsroom
Janux Therapeutics To Host Virtual Event On Monday, December 2, 2024, At 4:30 PM ET Discussing Updated Clinical Data In Phase 1a Dose Escalation For JANX007 In MCRPC And Doses Selected For Phase 1b Expansion Studies
Janux Therapeutics Initiated With an Outperform at Leerink
Evaluating Janux Therapeutics: Insights From 6 Financial Analysts
Janux Therapeutics Initiated at Outperform by Leerink Partners
Leerink Partners Initiates Janux Therapeutics(JANX.US) With Buy Rating, Announces Target Price $79
Innovative TRACTr Platform and Promising Prospects for Janux Therapeutics: An Analysis of JANX007's Potential in Prostate Cancer Treatment
10 Health Care Stocks Whale Activity In Today's Session
Analysts Offer Insights on Healthcare Companies: Janux Therapeutics Inc (JANX), 89bio (ETNB) and Ardent Health Partners, Inc. (ARDT)
Janux Therapeutics Analyst Ratings
Stifel Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $70
Cantor Fitzgerald Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $100
Analysts' Opinions Are Mixed on These Healthcare Stocks: CVS Health (CVS), Amicus (FOLD) and Janux Therapeutics Inc (JANX)
Janux Therapeutics Inc (JANX) Receives a Buy From Cantor Fitzgerald
H.C. Wainwright Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $63
Buy Rating for Janux Therapeutics Driven by Promising Pipeline and Strong Financial Position
BTIG Maintains Janux Therapeutics(JANX.US) With Buy Rating, Raises Target Price to $82
Janux Therapeutics GAAP EPS of -$0.51 Misses by $0.13, Revenue of $0.44M Misses by $1.23M
TD Cowen Maintains Janux Therapeutics(JANX.US) With Buy Rating
Promising Phase I Trial Results and Tolerability Boost Buy Rating for Janux Therapeutics' JANX007 in MCRPC Treatment
Janux Therapeutics | 10-Q: Q3 2024 Earnings Report